The Melbourne Biomedical Precinct, through its 30 Precinct Partners, delivers outstanding clinical care and education, and produces world-class biomedical research.
We excel particularly in child and adolescent health, cancer, mental health and neurosciences, infectious diseases, and healthy ageing. Both individually and collectively these organisations are globally recognised for their innovation and outstanding patient outcomes.
The Melbourne Biomedical Precinct’s five clinical research strengths are the areas where it will generate the strongest health and economic impact over the next 20 years.
They represent areas of comparative advantage for the Melbourne Biomedical Precinct based on research output, reputation, world-class expertise and landmark institutions and facilities.
Victoria’s expertise in these clinical research strengths is not limited to Precinct Partners and represent strong collaboration shared across the state’s wider biomedical ecosystem. More broadly, international collaboration across these (and other) research areas is what will enhance the world’s scientific knowledge more rapidly.
These five clinical research strengths are not the only areas of high-quality health research occurring in the Melbourne Biomedical Precinct. For example, Precinct Partners are also globally recognised in electrophysiology, dental research and maternal and women’s health.
The Melbourne Biomedical Precinct Partners have identified eight priority research platforms to position it in the global top 10. They reflect the Precinct's clinical research strengths, as well as global health and disease trends and the future of science and discovery Importantly and, they also provide some of the greatest opportunities for commercialisation.
While it is recognised these are not all the research platforms of the Melbourne Biomedical Precinct, this prioritisation helps guide the long term direction of Precinct Partners and help focus cooperation and alliances in and beyond the Precinct.